

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



07th August, 2025

To,
The Manager,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 539206

Company Symbol: GVBL

Sub: Outcome of the Board meeting Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on today i.e. 07th August 2025.

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at their meeting held on Thursday, 07th August 2025, at the Registered office of the Company situated at 4 K.M. Stone, Berri Chharra Road, Village - Kherka Musalman, P.O. Tandaheri, Tehsil - Bahadurgarh, Dist. Jhajjar, Bahadurgarh, Haryana - 124507 to consider and approve the following matter(s): -

1. Considered and approved the Un-audited financial results of the company for the quarter ended 30th June 2025. A copy of the said standalone un-audited financial results along with the limited review report from Statutory Auditor thereon is enclosed herewith;
2. Appointment of M/s. SBR & Co. LLP, Company Secretaries (LLP No. AAO-9057) as the Secretarial Auditors of the Company for Financial year 25-30.
The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, attached below as '**Annexure A**'.
3. Considered and approved the appointment of Mr. Navjyoti Kumar Jha as Internal Auditor of the company for the F.Y. 2025-26.
The details as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is annexed as '**Annexure-B**'.

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507



genomicvalley@gmail.com



www.genomicvalley.com



+91 9811341542



4. Re-appointment of Mr. Yogesh Agrawal as Chairman & Managing Director of the Company for the period of five (5) years with effect from 07.09.2025.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is annexed as '**Annexure-C**'.

The meeting of the Board of Directors commenced at 03:30 P.M. and concluded at 04:30 P.M.

This is for your information and record please.

Thanking you,
Yours sincerely,

For Genomic Valley Biotech Limited

Yogesh Agrawal
Managing Director
DIN : 01165288

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



Annexure-A

Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr. No.	Particulars	Details
a)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment
b)	Date of appointment/ reappointment/ cessation (as applicable) & term of appointment/re-appointment	Appointment is for Financial Year 2025-2030
c)	Brief profile (in case of appointment)	M/s SBR & Co. LLP, is a firm of Company Secretaries, established in the year 2019, based at Navi Mumbai and having branch office at Ghaziabad, with an experience of more than 6 years. M/s SBR & Co. LLP, Company Secretaries has been quality reviewed by the Institute of Company Secretaries of India (ICSI), peer reviewed by the ICSI.
d)	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507



genomicvalley@gmail.com



www.genomicvalley.com



+91 9811341542



Annexure-B

Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr. No.	Particulars	Details
a)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment
b)	Date of appointment/ reappointment/ cessation (as applicable) & term of appointment/re-appointment	The Board at its meeting held today i.e 07 th August, 2025 approved the appointment of Mr. Navjyoti Kumar Jha as Internal Auditor of the company for the FY 2025-26.
c)	Brief profile (in case of appointment)	Mr. Navjyoti Kumar Jha is having experience of 25 years. He has graduated with Degree in Bachelor of Commerce [(B.Com (H))].
d)	Disclosure of relationships between directors (in case of appointment of a director)	He is not related to any director of the Company.

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507



genomicvalley@gmail.com



www.genomicvalley.com



+91 9811341542



Annexure-C

Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr. No.	Particulars	Details
a)	Name of Director	Mr. Yogesh Agrawal
b)	Age	62 Yr
c)	Qualification	B.Com (H) & Chartered Accountant
d)	Experience (including expertise in specific functional area) / Brief Resume	He is having wide experience in business activities right from the beginning of his career. He successfully operated several Private Limited and Public Limited Companies during his 35 years of exposure. Under his able and experienced guidance and direction M/s Genomic Valley Biotech Limited is progressing well in leaps and bound. He is one of the promoters of the Company.
e)	Terms and Conditions of Appointment / Re-appointment	As per Agreement
f)	Remuneration last drawn as director (including sitting fees, if any) (in Rs.)	2,50,000/-
g)	Remuneration proposed to be paid	As per Agreement
h)	Date of first appointment on the Board	07.09.2015
i)	Shareholding in the Company as on March 31, 2025	14,27,000 Eq. shares
j)	Relationship with other Directors / Key Managerial Personnel	Husband of Mrs. Parul Agrawal, Director of the Company
k)	Number of meetings of the Board attended during the year (as director) 2024-25	6
l)	Directorships of other Boards as on March 31, 2025.	1. Genomic Valley Bharat Private Limited 2. Eyoge Media Entertainment Private Limited 3. Kannu Aditya (India) Limited 4. Rishikesh School of Yoga Foundation 5. UCC Entertainment Media Private Limited
m)	Membership / Chairmanship of Committees of other Boards as on March 31, 2025.	NIL

ANDROS & CO.

Chartered Accountants



901 , 9th floor , Tower 1
Pearls Omaxe , Plot B-1
Netaji Subhash Place (NSP) ,
Pitampura , New Delhi 110034
Email: cabhavukgarg@gmail.com
Phone : 47060901 , 9560438787

LIMITED REVIEW REPORT

To

the Board of Directors

Genomic Valley Biotech Limited

4 K.M.Stone, Berri Chharra Road


Vill. Kherka, Musalman, P.O. Tandaheri Teh Bahadu , Jhajjar,

Haryana – 124507

1. Introduction

We have reviewed the accompanying statement of unaudited financial results of **Genomic Valley Biotech Limited** ("the Company") for the quarter and year-to-date period ended **30th June 2025** ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the **SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015** as amended ("Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the **Indian Accounting Standard 34 ('Ind AS 34'), 'Interim Financial Reporting'**, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.



2. Scope of Review

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, '**Review of Interim Financial Information Performed by the Independent Auditor of the Entity**', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.

A review is substantially less in scope than an audit conducted in accordance with **Standards on Auditing (SAs)** and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


3. Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Andros & Co.**

Chartered Accountants,

FRN No.: 0008976N




CA Bhavuk Garg

Partner

Membership No. 502310

Place: New Delhi

Date : 07.08.2025



UDIN : 25502310-BMGUID-6193

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Genomic Valley Biotech Limited today reported its financial performance for the quarter ended
30 June 2025

Highlights of the Un-Audited Financial Results as compared to the previous year are:

Part I		In Rs.			
Sr. No.	Particular	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Previous year ended
		30-Jun-25 Un-Audited	31-Mar-25 Audited	30-Jun-24 Un-Audited	31-Mar-25 Audited
I	Revenue From Operations	9,00,000	26,35,094	15,53,350	84,39,394
II	Other Income	-	676	-	44,660
III	Total Revenue (I+II)	9,00,000	26,35,770	15,53,350	84,84,054
IV	Expenses				
	Cost of materials consumed	-	-	-	-
	Purchases of Stock-in-Trade	-	48,56,220	-	48,56,220
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-28,42,425	-	-28,42,425
	Employee benefits expense	4,14,000	4,14,000	1,20,000	12,08,645
	Financial costs	-	-	-	-
	Depreciation and amortization expense	8,000	10,414	-	25,414
	Other expenses	2,31,469	1,79,012	1,57,447	8,21,824
	Total Expenses (IV)	6,53,469	26,17,222	2,77,447	40,69,678
V	Profit / (Loss) before exceptional item and tax (III-IV)	2,46,531	18,548	12,75,903	44,14,376
VI	Exceptional Item	-	-	-	-
VII	Profit/Loss before Tax (V-VI)	2,46,531	18,548	12,75,903	44,14,376
VIII	Tax expenses				
	(1) Current Tax	-	8,50,000	-	8,50,000
	(2) Deferred Tax	-	3,444	-	3,444
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	2,46,531	-8,34,895	12,75,903	35,60,932
X	Profit/ (Loss) from discontinued operations	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	2,46,531	-8,34,895	12,75,903	35,60,932
XIV	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	2,46,531	-8,34,895	12,75,903	35,60,932
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	30,54,500	30,54,500	30,54,500	30,54,500
XVII	Earning Per Equity Share (for continuing operation):				
	1) Basic	0.08	-0.27	0.42	1.17
	2) Diluted	0.08	-0.27	0.42	1.17
XVIII	Earning Per Equity Share (for discontinued operation):				
	1) Basic	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):				
	1) Basic	0.08	-0.27	0.42	1.17
	2) Diluted	0.08	-0.27	0.42	1.17

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on 07.08.2025. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited



Place : Delhi
Dated : 07.08.2025

(Signature)
Yogesh Agrawal
(Managing Director)
DIN-01165288
Add: G-74 Pushkar Enclave
Paschim Vihar, New Delhi-110063